Clinical Trials Browser

Phase 1/2 × Neoplasms × S-1,2-dichlorovinyl-N-acetylcysteine × Clear all

NCT04085159 2020-06-12

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Phase 1/2 Unknown

Neoplasms